{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:30:24Z","timestamp":1780446624883,"version":"3.54.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T00:00:00Z","timestamp":1642896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T00:00:00Z","timestamp":1642896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Center for Human Reproduction"},{"name":"The Foundation for Reproductive Medicine"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Assist Reprod Genet"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Growth hormone (GH) supplementation in association with in vitro fertilization (IVF) is worldwide again increasing, even though study outcomes have been discrepant. Since GH acts via insulin-like growth factor-1 (IGF-1), its utilization in IVF would only seem to make sense with low IGF-1. We, therefore, determined whether IGF-I levels affect IVF outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Retrospectively, 302 consecutive first fresh, non-donor IVF cycles were studied, excluding patients on GH supplementation. Patients were divided into 3 subgroups: IGF-1 in lower 25th percentile (group A,\u2009&lt;\u2009132\u00a0ng\/mL,<jats:italic>n<\/jats:italic>\u2009=\u200964); 25th\u201375th percentile (B, 133\u2013202\u00a0ng\/mL,<jats:italic>n<\/jats:italic>\u2009=\u2009164), and upper 25th percentile (C,\u2009&gt;\u2009202\u00a0ng\/mL,<jats:italic>n<\/jats:italic>\u2009=\u200974). IGF-1 was tested immunochemiluminometric with normal range at 78\u2013270\u00a0ng\/mL. Because of the study patients\u2019 adverse selection and low pregnancy chances, the main outcome measure for the study was cycle cancellation. Secondary outcomes were oocyte numbers, embryos transferred, pregnancies, and live births.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Group A was significantly older than B and C (<jats:italic>P<\/jats:italic>\u2009=\u20090.019). IGF-1 decreased with increasing age per year by 2.2\u2009\u00b1\u20090.65\u00a0ng\/mL (<jats:italic>P<\/jats:italic>\u2009=\u20090.0007). FSH was best in group B and worst in A (trend,<jats:italic>P<\/jats:italic>\u2009=\u20090.085); AMH was best in B and worst in A (N.S.). Cycle cancellations were lowest in C (11.6%) and highest in A (25.0%;<jats:italic>P<\/jats:italic>\u2009=\u20090.042). This significance further improved with age adjustment (<jats:italic>P<\/jats:italic>\u2009=\u20090.021). Oocytes, embryo numbers, pregnancies, and live birth rates did not differ, though oocyte numbers trended highest in B.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Here presented results support the hypothesis that IGF-1 levels affect IVF outcomes. GH treatments, therefore, may be effective only with low IGF-1.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s10815-021-02379-8","type":"journal-article","created":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T00:03:55Z","timestamp":1642896235000},"page":"409-416","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Importance of IGF-I levels in IVF: potential relevance for growth hormone (GH) supplementation"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0202-4167","authenticated-orcid":false,"given":"Norbert","family":"Gleicher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah K.","family":"Darmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Molinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Patrizio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David. H.","family":"Barad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,23]]},"reference":[{"issue":"1","key":"2379_CR1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1365-2265.1988.tb00252.x","volume":"29","author":"R Homburg","year":"1988","unstructured":"Homburg R, Eshel A, Abdalla HI, Jacobs HS. Growth hormone facilitates ovulation induction by gonadotrophins. Clin Endocrinol (Oxf). 1988;29(1):113\u20137.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"2379_CR2","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/S0015-0282(16)54724-4","volume":"56","author":"EJ Owen","year":"1991","unstructured":"Owen EJ, Ostergaard H, Shoham Z, Jacobs HS. Cotreatment with growth hormone, after pituitary suppression, for ovarian stimulation in in vitro fertilization: a randomized, double-blind, placebo-controlled trial. Fertil Steril. 1991;56(6):1105\u201310.","journal-title":"Fertil Steril"},{"key":"2379_CR3","first-page":"12","volume":"96","author":"X-L Li","year":"2017","unstructured":"Li X-L, Wang L, Fang LV, Huang X-M, Wang L-P, Pan Y, Zhang X-M. The influence of different growth hormone addition protocols to poor ovarian responders on clinical outcomes in controlled ovary stimulation cycles. A systematic review and meta-analysis. System Rev Meta-Analyses. Medicine. 2017;96:12.","journal-title":"Medicine"},{"issue":"650","key":"2379_CR4","first-page":"1","volume":"19","author":"JL Yovich","year":"2019","unstructured":"Yovich JL, Regan SLP, Zaid S, Keane KN. The concept of growth hormone deficiency affecting clinical prognosis in IVF. Front Endocrinol. 2019;19(650):1\u20139.","journal-title":"Front Endocrinol"},{"issue":"502","key":"2379_CR5","first-page":"1","volume":"10","author":"Y-M Xu","year":"2019","unstructured":"Xu Y-M, Hao G-M, Gao B-L. Application of growth hormone in in vitro fertilization. Front Endocrinol. 2019;10(502):1\u201311.","journal-title":"Front Endocrinol"},{"key":"2379_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2020.00001","volume":"11","author":"J Zhu","year":"2020","unstructured":"Zhu J, Wang Y, Chen L, Liu P, Li R, Qiao J. Growth hormone supplementation may not improve live birth rates in poor responders. Front Endocrinol. 2020;11:1\u20139.","journal-title":"Front Endocrinol"},{"key":"2379_CR7","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3389\/fendo.2019.00500","volume":"10","author":"RJ Hart","year":"2019","unstructured":"Hart RJ. Use of growth hormone in the IVF treatment of women with poor ovarian reserve. Front Endocrinol (Lausanne). 2019;10:500.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2379_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2019.00777","volume":"10","author":"E Ipsa","year":"2019","unstructured":"Ipsa E, Cruzat VF, Kagize JN, Yovich JL, Keane KN. Growth hormone and insulin-like growth factor action in reproductive tissues. Front Endocrinol (Lausanne). 2019;10:1\u201314.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"2379_CR9","doi-asserted-by":"publisher","first-page":"356.e1","DOI":"10.1016\/j.ajog.2015.04.026","volume":"213","author":"I Ramer","year":"2015","unstructured":"Ramer I, Kanninen TK, Sisti G, Witkin SS, Spandorfer SD. Association of in vitro fertilization outcomes with circulating insulin-like growth factor components prior to cycle initiation. Am J Obstet Gynecol. 2015;213(3):356.e1-6.","journal-title":"Am J Obstet Gynecol"},{"issue":"12","key":"2379_CR10","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1007\/s10815-019-01618-3","volume":"36","author":"D Nasioudis","year":"2019","unstructured":"Nasioudis D, Minis E, Irani M, Kreines F, Witkin S, Spandorefer S. Insulin-like growth favtor-1 and soluble FMS-like tyrosine kinase-1 prospectively predict cancelled IVF cycles. J Assist Reprod Genet. 2019;36(12):2485\u201391.","journal-title":"J Assist Reprod Genet"},{"key":"2379_CR11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s10815-011-9543-7","volume":"28","author":"G Genc","year":"2011","unstructured":"Genc G, Yilmaz N, Uygur D. The effect of intrafollicular IGF 1 and IGFBP 3 on IVF outcome in patients using different gonadotropins: a prospective study. J Assist Reprod Genet. 2011;28:405\u201310.","journal-title":"J Assist Reprod Genet"},{"key":"2379_CR12","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.2337\/db11-1300","volume":"61","author":"N Barzilai","year":"2012","unstructured":"Barzilai N, Huffman DM, Muzumdar RH, Bartke A. A critical role of metabolic pathways in aging. Diabetes. 2012;61:1315\u201322.","journal-title":"Diabetes"},{"key":"2379_CR13","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3389\/fgene.2018.00586","volume":"9","author":"A Bartke","year":"2018","unstructured":"Bartke A, Quainoo N. Impact of growth hormone -related mutations on mammalian aging. Front Genet. 2018;9:586. https:\/\/doi.org\/10.3389\/fgene.2018.00586.","journal-title":"Front Genet"},{"key":"2379_CR14","doi-asserted-by":"publisher","first-page":"3438","DOI":"10.1073\/pnas.0705467105","volume":"105","author":"Y Suh","year":"2008","unstructured":"Suh Y, Atzmon G, Cho MO, Hwang D, Liu B, Leahy DJ, Barzilai N, Cohen P. Functional significant insulin-like growth factor I receptor mutations in centenarians. Proc Nat Acad Sci USA. 2008;105:3438\u201342.","journal-title":"Proc Nat Acad Sci USA"},{"key":"2379_CR15","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/j.1474-9726.2011.00697.x","volume":"10","author":"C Tazearslan","year":"2011","unstructured":"Tazearslan C, Huang J, Barzilai N, Suh Y. impaired IGF1R signaling in cells expressing longevity-associated human IGF1R alleles. Aging Cell. 2011;10:551\u20134.","journal-title":"Aging Cell"},{"key":"2379_CR16","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/acel.12213","volume":"13","author":"S Milamn","year":"2014","unstructured":"Milamn S, Atzmon G, Huffman DM, Wan J, Crandall JP, Cohen P, Barzilai N. Low insulin-like-growth factor 1 level predicts survival in humans with exceptional longevity. Aging Cell. 2014;13:769\u201371.","journal-title":"Aging Cell"},{"key":"2379_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2019.00404","volume":"10","author":"C Dosouto","year":"2019","unstructured":"Dosouto C, Calaf J, Polo A, Haahr T, Humaidan P. Growth hormone and reproduction: Lessons learned from animal models and clinical trials. Front Endocrinol. 2019;10:1\u20137.","journal-title":"Front Endocrinol"},{"issue":"3","key":"2379_CR18","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1210\/er.2010-0009","volume":"32","author":"EO List","year":"2011","unstructured":"List EO, Sackman-Sala L, Berryman DE, Funk K, Kelder B, Gosney ES, Okada S, Ding J, Cruz-Topete D, Kpchick JJ. Endocrine parameters and phenotypes of te growth hormone receptor gene disrupted (GHR-\/-) mouse. Endocr Rev. 2011;32(3):356\u201386.","journal-title":"Endocr Rev"},{"key":"2379_CR19","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1530\/rep.1.00946","volume":"131","author":"KA Slot","year":"2006","unstructured":"Slot KA, Kastelijn J, Bachelot A, Kelly PA, Binart N, Teerds KJ. Reduced recruitment and survival of primordial and growing follicles in GH receptor-deficient mice. Reprod Camb Engl. 2006;131:525\u201332.","journal-title":"Reprod Camb Engl"},{"key":"2379_CR20","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1210\/endo-121-4-1343","volume":"121","author":"CH Hsu","year":"1987","unstructured":"Hsu CH, Hammond JM. Concomitant effects of growth hormone on secretion of insulin -like growth factor I and progesterone by cultured porcine granulosa cells. Endocrinology. 1987;121:1343\u20138.","journal-title":"Endocrinology"},{"issue":"3","key":"2379_CR21","doi-asserted-by":"publisher","first-page":"R141","DOI":"10.1530\/JOE-14-0296","volume":"222","author":"H Prizant","year":"2014","unstructured":"Prizant H, Gleicher N, Sen A. Androgen actions in the ovary: Balance is key. J Endocrinol. 2014;222(3):R141-151.","journal-title":"J Endocrinol"},{"key":"2379_CR22","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1477-7827-9-67","volume":"9","author":"N Gleicher","year":"2011","unstructured":"Gleicher N, Barad DH. Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR). Reprod Biol Endocrinol. 2011;9:67.","journal-title":"Reprod Biol Endocrinol"},{"issue":"3","key":"2379_CR23","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/S0015-0282(97)00575-X","volume":"69","author":"ES Surrey","year":"1998","unstructured":"Surrey ES, Bower J, Hill DM, Ramsey J, Surrey MW. Clinical and endocrine effects of a microdose GnRH agonist flare regimen administered to poor responders who are undergoing in vitro fertilization. Fertil Steril. 1998;69(3):419\u201324.","journal-title":"Fertil Steril"},{"issue":"3","key":"2379_CR24","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1530\/JOE-15-0246","volume":"226","author":"Y-G Wu","year":"2015","unstructured":"Wu Y-G, Barad DH, Kushnir VA, Lazzaroni E, Wang Q, Albertini DF, Gleicher N. Aging-related premature luteinization of granulosa cells is avoided by early oocyte retrieval. J Endocrinol. 2015;226(3):167\u201380.","journal-title":"J Endocrinol"},{"issue":"1","key":"2379_CR25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13048-018-0398-8","volume":"11","author":"Y-G Wu","year":"2018","unstructured":"Wu Y-G, Barad DH, Kushnir VA, Wang Q, Zhang L, Darmon SK, Albertini DH, Gleicher N. With low ovarian reserve, highly individualized egg retrieval (HIER) improves IVF results by avoiding premature luteinization. J Ov Res. 2018;11(1):23. https:\/\/doi.org\/10.1186\/s13048-018-0398-8.","journal-title":"J Ov Res"},{"issue":"1","key":"2379_CR26","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s12020-015-0744-1","volume":"52","author":"H-J Lee","year":"2016","unstructured":"Lee H-J, Barad DH, Kushnir VA, Shohat-Tal A, Lazzaroni-Tealdi E, Wu Y-G, Gleicher N. Rescue in vitro maturation (IVM) of immarure oocytes in stimulated cycles in women with low functional ovarian reserve (LFOR). Endocrine. 2016;52(1):165\u201371.","journal-title":"Endocrine"},{"issue":"6","key":"2379_CR27","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.fertnstert.2020.02.111","volume":"113","author":"L Man","year":"2020","unstructured":"Man L, Levkovich J, Canon C, Rosenwaks Z. Cycle day2 insulin-like growth factor-1 serum levels as a prognostic tool to predict controlled ovarian hyperstimulation outcomes in poor responders. Fertil Steril. 2020;113(6):1205\u201314.","journal-title":"Fertil Steril"},{"issue":"6","key":"2379_CR28","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.fertnstert.2020.04.047","volume":"113","author":"EJ Forman","year":"2020","unstructured":"Forman EJ. In search of a new biomarker to predict poor ovarian response. Fertil Steril. 2020;113(6):111.","journal-title":"Fertil Steril"},{"key":"2379_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1023\/A:1022448532248","volume":"4","author":"A Bartke","year":"2003","unstructured":"Bartke A, Chandrashekar V, Dominici F, Turyn D, Kinney B, Steger R, Kopchick JJ. Insulin-like growth factor 1 (IGF-1) and aging: controversies and new insights. Biogerontology. 2003;4:1\u20138.","journal-title":"Biogerontology"},{"key":"2379_CR30","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1530\/REP-18-0529","volume":"157","author":"H-Y Hou","year":"2019","unstructured":"Hou H-Y, Wang X, Yu Q, Li H-Y, Li S-J, Tang R-Y, Guo Z-X, Chen Y-Q, Hu C-X, Yang Z-J, Zhang W-k, Qin Y. Evidence that growth hormone can improve mitochondriak fucntion in oocytes from aged mice. Reproduction. 2019;157:345\u201358.","journal-title":"Reproduction"},{"key":"2379_CR31","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1023\/A:1016630603560","volume":"18","author":"HA Hassan","year":"2001","unstructured":"Hassan HA, Azab H, Abdel Rahman A. Effects of growth hormone on in vitro maturation of germinal vesicle of human oocytes retrieved from small antral follicles. J Assist Reprod Genet. 2001;18:417\u201320.","journal-title":"J Assist Reprod Genet"},{"key":"2379_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2019.00653","volume":"10","author":"S Altm\u00e4e","year":"2019","unstructured":"Altm\u00e4e S, Aghajanova L. Growth hormone and endometrial receptivity. Front Endocrinol. 2019;10:1\u201311. https:\/\/doi.org\/10.3389\/fendo.2019.00653.","journal-title":"Front Endocrinol"},{"key":"2379_CR33","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12967-016-0924-7","volume":"14","author":"N Gleicher","year":"2016","unstructured":"Gleicher N, Kushnir V, Sen A, Darmon SK, Weghofer A, Wu Y-G, Wang Q, Zhang L, Albertini DF, Barad DH. Definition by FSH, AMH and embryo numbers of good-, intermediate- and poor prognosis patients suggests previously unknown IVF outcome-determining factor associated with AMH. J Transl Med. 2016;14:172.","journal-title":"J Transl Med"},{"key":"2379_CR34","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jri.2018.03.002","volume":"127","author":"M Irani","year":"2018","unstructured":"Irani M, Nasioudis D, Witkin SS, Gunnala V, Spandorefer S. High serum IGF-1 levels are associated with pregnancy loss following frozen-thawed euploid embryo transfer cycles. J Reprod Immunol. 2018;127:7\u201310.","journal-title":"J Reprod Immunol"},{"key":"2379_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2019.00485","volume":"10","author":"Y Li","year":"2019","unstructured":"Li Y, Liu H, Yu Q, Liu H, Huang T, Zhao S, Ma J, Zhao H. Growth hormone promotes in vitro maturation of human oocytes. Front Endocrinol. 2019;10:1\u20138. https:\/\/doi.org\/10.3389\/fendo.2019.00485.","journal-title":"Front Endocrinol"},{"key":"2379_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2020.00049","volume":"11","author":"F-T Liu","year":"2020","unstructured":"Liu F-T, Wu Z, Yan J, Norman RJ, Li R. The potential role of growth hormone on the endometrium in assisted reproductive technology. Front Endocrinol. 2020;11:1\u20138. https:\/\/doi.org\/10.3389\/fendo.2020.00049.","journal-title":"Front Endocrinol"}],"container-title":["Journal of Assisted Reproduction and Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10815-021-02379-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10815-021-02379-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10815-021-02379-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T04:07:03Z","timestamp":1700107623000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10815-021-02379-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,23]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["2379"],"URL":"https:\/\/doi.org\/10.1007\/s10815-021-02379-8","relation":{},"ISSN":["1058-0468","1573-7330"],"issn-type":[{"value":"1058-0468","type":"print"},{"value":"1573-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,23]]},"assertion":[{"value":"11 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the IRB of The CHR. All patients in this study signed an informed consent that allowed use of their medical record for research purposes if their identity was protected, and the material remained confidential. Since this study involved only use of deidentified electronic medical records, these conditions were met.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Above noted approval also includes a consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"N.G. and D.H.B. are listed as co-owners of several already awarded and still pending US patents, some claiming benefits from androgen supplementation in women with low functional ovarian reserve, a topic peripherally addressed in this manuscript. Others relate to diagnostic and potential therapeutic benefits of AMH, also marginally addressed in this manuscript. N.G. is a shareholder in Fertility Nutraceuticals, LLC, which produces a DHEA product, and is owner of The CHR., where much of the research reported in this manuscript was performed. N.G. and D.H.B. also receive patent royalties from Fertility Nutraceuticals, LLC. N.G., P.P., and D.H.B. also received research support, travel funding, and lecture fees from various Pharma and medical device companies, none, however, over the last 3\u00a0years and none in any way related to this manuscript. Other authors have no conflicts to report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}